Free Trial

Crescent Biopharma (CBIO) Competitors

Crescent Biopharma logo
$10.25 -1.10 (-9.69%)
As of 10/13/2025 04:00 PM Eastern

CBIO vs. ZBIO, GERN, MYGN, VSTM, LXRX, RIGL, EBS, XOMA, VNDA, and IRWD

Should you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include Zenas BioPharma (ZBIO), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

Crescent Biopharma vs. Its Competitors

Crescent Biopharma (NASDAQ:CBIO) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Zenas BioPharma had 47 more articles in the media than Crescent Biopharma. MarketBeat recorded 49 mentions for Zenas BioPharma and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 1.91 beat Zenas BioPharma's score of 0.48 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crescent Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Zenas BioPharma
13 Very Positive mention(s)
6 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

75.2% of Crescent Biopharma shares are owned by institutional investors. 8.7% of Crescent Biopharma shares are owned by insiders. Comparatively, 16.5% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Crescent Biopharma currently has a consensus target price of $25.60, suggesting a potential upside of 149.76%. Zenas BioPharma has a consensus target price of $38.33, suggesting a potential upside of 44.44%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Crescent Biopharma is more favorable than Zenas BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crescent Biopharma
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.33
Zenas BioPharma
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Crescent Biopharma has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescent Biopharma$10K20,038.75-$37.88M-$34.93-0.29
Zenas BioPharma$5M223.52-$156.99M-$3.55-7.48

Zenas BioPharma's return on equity of -59.21% beat Crescent Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Crescent BiopharmaN/A -106.06% -86.60%
Zenas BioPharma N/A -59.21%-50.56%

Summary

Crescent Biopharma beats Zenas BioPharma on 9 of the 15 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CBIO vs. The Competition

MetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$221.89M$2.61B$6.05B$10.30B
Dividend YieldN/A57.78%5.73%4.82%
P/E Ratio-0.2922.5785.1927.10
Price / Sales20,038.75755.26597.83133.24
Price / CashN/A26.3325.7730.18
Price / Book1.245.3512.626.69
Net Income-$37.88M$33.06M$3.32B$276.55M
7 Day Performance-9.21%0.13%-0.04%-0.40%
1 Month Performance-17.93%9.75%8.73%6.53%
1 Year PerformanceN/A-1.04%78.10%41.04%

Crescent Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CBIO
Crescent Biopharma
4.3412 of 5 stars
$10.25
-9.7%
$25.60
+149.8%
N/A$221.89M$10K-0.2950Positive News
ZBIO
Zenas BioPharma
2.2276 of 5 stars
$20.85
-9.5%
$36.67
+75.9%
N/A$877.99M$15M-5.87N/AAnalyst Revision
High Trading Volume
GERN
Geron
2.4953 of 5 stars
$1.29
+0.8%
$3.79
+193.5%
-70.7%$823.05M$76.99M-9.9270News Coverage
MYGN
Myriad Genetics
3.6415 of 5 stars
$7.53
-5.8%
$12.45
+65.4%
-67.4%$700.59M$837.60M-1.762,700
VSTM
Verastem
2.8797 of 5 stars
$9.00
+4.5%
$13.29
+47.6%
+212.8%$553.86M$10K-2.7450
LXRX
Lexicon Pharmaceuticals
2.7263 of 5 stars
$1.52
-1.9%
$3.23
+112.2%
-17.2%$552.37M$31.08M-4.61140Positive News
Gap Up
RIGL
Rigel Pharmaceuticals
3.7815 of 5 stars
$29.50
+2.1%
$38.20
+29.5%
+73.9%$529.14M$267.92M5.45160
EBS
Emergent Biosolutions
4.312 of 5 stars
$9.91
+8.4%
$13.50
+36.3%
+6.4%$528.43M$1.04B4.042,420
XOMA
XOMA Royalty
4.0914 of 5 stars
$37.16
+1.5%
$69.50
+87.0%
+31.1%$449.26M$28.49M-23.9710
VNDA
Vanda Pharmaceuticals
4.0932 of 5 stars
$5.32
-1.5%
$16.50
+210.2%
+17.8%$314.36M$198.77M-4.71290
IRWD
Ironwood Pharmaceuticals
4.4545 of 5 stars
$1.52
+2.7%
$4.94
+225.0%
-65.3%$246.90M$308.52M-30.39220News Coverage
Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:CBIO) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners